Literature DB >> 22286369

Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction.

Tatiane M Murça1, Tatiane C S Almeida, Mohan K Raizada, Anderson J Ferreira.   

Abstract

In this study, we evaluated whether the activation of endogenous angiotensin-converting enzyme 2 (ACE2) would improve the cardiovascular autonomic dysfunction of diabetic rats. Ten days after induction of type 1 diabetes (streptozotocin, 50 mg kg(-1) i.v.), the rats were treated orally with 1-[(2-dimethylamino)ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one (XNT), a newly discovered ACE2 activator (1 mg kg(-1) day(-1)), or saline (equivalent volume) for 30 days. Autonomic cardiovascular parameters were evaluated in conscious animals, and an isolated heart preparation was used to analyse cardiac function. Diabetes induced a significant decrease in the baroreflex bradycardia sensitivity, as well as in the chemoreflex chronotropic response and parasympathetic tone. The XNT treatment improved these parameters by ≈ 76% [0.82 ± 0.09 versus 1.44 ± 0.17 Ratio between changes in pulse interval and changes in mean arterial pressure (ΔPI/ΔmmHg)], ∼85% (-57 ± 9 versus -105 ± 10 beats min(-1)) and ≈ 205% (22 ± 2 versus 66 ± 12 beats min(-1)), respectively. Also, XNT administration enhanced the bradycardia induced by the chemoreflex activation by v 74% in non-diabetic animals (-98 ± 16 versus -170 ± 9 Δbeats min(-1)). No significant changes were observed in the mean arterial pressure, baroreflex tachycardia sensitivity, chemoreflex pressor response and sympathetic tone among any of the groups. Furthermore, chronic XNT treatment ameliorated the cardiac function of diabetic animals. However, the coronary vasoconstriction observed in diabetic rats was unchanged by ACE2 activation. These findings indicate that XNT protects against the autonomic and cardiac dysfunction induced by diabetes. Thus, our results provide evidence for the viability and effectiveness of oral administration of an ACE2 activator for the treatment of the cardiovascular autonomic dysfunction caused by diabetes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286369      PMCID: PMC3350618          DOI: 10.1113/expphysiol.2011.063461

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  82 in total

1.  Altered cardiovascular reflexes responses in conscious Angiotensin-(1-7) receptor Mas-knockout mice.

Authors:  Marina Matos de Moura; Robson Augusto Souza dos Santos; Maria José Campagnole-Santos; Mihail Todiras; Michael Bader; Natalia Alenina; Andréa Siqueira Haibara
Journal:  Peptides       Date:  2010-07-21       Impact factor: 3.750

2.  Role of blood flow in carotid body chemoreflex function in heart failure.

Authors:  Yanfeng Ding; Yu-Long Li; Harold D Schultz
Journal:  J Physiol       Date:  2010-11-15       Impact factor: 5.182

3.  Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2.

Authors:  JiuChang Zhong; Danny Guo; Christopher B Chen; Wang Wang; Manfred Schuster; Hans Loibner; Josef M Penninger; James W Scholey; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Hypertension       Date:  2010-12-28       Impact factor: 10.190

4.  Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse.

Authors:  Merlin C Thomas; Raelene J Pickering; Despina Tsorotes; Audrey Koitka; Karen Sheehy; Stella Bernardi; Barbara Toffoli; Thu-Phuc Nguyen-Huu; Geoffrey A Head; Yi Fu; Jaye Chin-Dusting; Mark E Cooper; Chris Tikellis
Journal:  Circ Res       Date:  2010-07-29       Impact factor: 17.367

5.  Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes.

Authors:  Julian W Sacre; Bennett Franjic; Christine L Jellis; Carly Jenkins; Jeff S Coombes; Thomas H Marwick
Journal:  JACC Cardiovasc Imaging       Date:  2010-12

6.  Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice.

Authors:  Sean E Thatcher; Xuan Zhang; Deborah A Howatt; Hong Lu; Susan B Gurley; Alan Daugherty; Lisa A Cassis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-20       Impact factor: 8.311

7.  Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases.

Authors:  Anderson J Ferreira; Vinayak Shenoy; Yanfei Qi; Rodrigo A Fraga-Silva; Robson A S Santos; Michael J Katovich; Mohan K Raizada
Journal:  Exp Physiol       Date:  2010-12-10       Impact factor: 2.969

Review 8.  Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments.

Authors:  Solomon Tesfaye; Andrew J M Boulton; Peter J Dyck; Roy Freeman; Michael Horowitz; Peter Kempler; Giuseppe Lauria; Rayaz A Malik; Vincenza Spallone; Aaron Vinik; Luciano Bernardi; Paul Valensi
Journal:  Diabetes Care       Date:  2010-10       Impact factor: 19.112

9.  Protective effect of the daming capsule on impaired baroreflexes in STZ-induced diabetic rats with hyperlipoidemia.

Authors:  Jing Ai; Li-Hong Wang; Rong Zhang; Guo-Fen Qiao; Ning Wang; Li-Hua Sun; Guan-Yi Lu; Chao Sun; Bao-Feng Yang
Journal:  BMC Complement Altern Med       Date:  2010-12-22       Impact factor: 3.659

10.  Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice.

Authors:  Sharell M Bindom; Chetan P Hans; Huijing Xia; A Hamid Boulares; Eric Lazartigues
Journal:  Diabetes       Date:  2010-07-26       Impact factor: 9.461

View more
  14 in total

1.  Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction.

Authors:  Tatiane M Murça; Patrícia L Moraes; Carolina A B Capuruço; Sérgio H S Santos; Marcos B Melo; Robson A S Santos; Vinayak Shenoy; Michael J Katovich; Mohan K Raizada; Anderson J Ferreira
Journal:  Regul Pept       Date:  2012-05-14

Review 2.  New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?

Authors:  Anna Gromotowicz-Poplawska; Piotr Szoka; Patrycjusz Kolodziejczyk; Karol Kramkowski; Marzena Wojewodzka-Zelezniakowicz; Ewa Chabielska
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-19

3.  Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro.

Authors:  Philipp K Haber; Minghao Ye; Jan Wysocki; Christoph Maier; Syed K Haque; Daniel Batlle
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

Review 4.  Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.

Authors:  Vaibhav B Patel; Jiu-Chang Zhong; Maria B Grant; Gavin Y Oudit
Journal:  Circ Res       Date:  2016-04-15       Impact factor: 17.367

Review 5.  Key developments in renin-angiotensin-aldosterone system inhibition.

Authors:  Bruno Sevá Pessôa; Nils van der Lubbe; Koen Verdonk; Anton J M Roks; Ewout J Hoorn; A H Jan Danser
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 6.  Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.

Authors:  Rodrigo Araujo Fraga-Silva; Anderson Jose Ferreira; Robson Augusto Souza Dos Santos
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

7.  Angiotensin-converting enzyme 2 activation improves endothelial function.

Authors:  Rodrigo A Fraga-Silva; Fabiana P Costa-Fraga; Tatiane M Murça; Patrícia L Moraes; Augusto Martins Lima; Roberto Q Lautner; Carlos H Castro; Célia Maria A Soares; Clayton L Borges; Ana Paula Nadu; Marilene L Oliveira; Vinayak Shenoy; Michael J Katovich; Robson A S Santos; Mohan K Raizada; Anderson J Ferreira
Journal:  Hypertension       Date:  2013-04-22       Impact factor: 10.190

8.  Combination of angiotensin-(1-7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy.

Authors:  Panpan Hao; Jianmin Yang; Yanping Liu; Mingxiang Zhang; Kai Zhang; Fei Gao; Yuguo Chen; Cheng Zhang; Yun Zhang
Journal:  Sci Rep       Date:  2015-03-05       Impact factor: 4.379

9.  Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina.

Authors:  G Foureaux; B S Nogueira; D C O Coutinho; M K Raizada; J C Nogueira; A J Ferreira
Journal:  Braz J Med Biol Res       Date:  2015-09-29       Impact factor: 2.590

10.  Stimulation of the ACE2/Ang-(1-7)/Mas axis in hypertensive pregnant rats attenuates cardiovascular dysfunction in adult male offspring.

Authors:  Amanda S M Bessa; Érika F Jesus; Allancer D C Nunes; Carolina N R Pontes; Ismaley S Lacerda; Jaqueline M Costa; Elisângela J Souza; Ruy S Lino-Júnior; Manoel F Biancardi; Fernanda C A Dos Santos; Gustavo R Pedrino; Diego B Colugnati; Renata Mazaro-Costa; Elizabeth P Mendes; Carlos H Castro
Journal:  Hypertens Res       Date:  2019-09-10       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.